Avalo Therapuetics (AVTX) Misses Q2 EPS by 25c

Avalo Therapuetics (NASDAQ: AVTX) reported Q2 EPS of ($0.83), $0.25 worse than the analyst estimate of ($0.58).

For earnings history and earnings-related data on Avalo Therapuetics (AVTX) click here.

You May Also Be Interested In

• Raymond James Starts Rocket Lab USA (RKLB) at Outperform
• US diesel hits record $6.06 a gallon as Iran war squeezes supply
• Lazard AUM rises to $290.3 billion at end of August 2026